Objective Coronavirus disease 19 (COVID-19) has an increased risk of coagulopathy with
high frequency of antiphospholipid antibodies (aPL). Recent reports of thrombosis …

Objective To explore whether inactivated coronavirus disease 2019 vaccine influences the
profile of prothrombotic autoantibodies and induces thrombotic events in primary APS …

Thrombosis is one of the many signs of antiphospholipid syndrome (APS) and COVID-19
infection. Although the mechanisms contributing to thrombosis in APS and COVID-19 are …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus discovered
in December 2019 that causes coronavirus disease 19 (COVID-19) and various …

Objectives Patients with APS and triple-positive for aPL are at high risk of recurrent events.
As COVID-19 and COVID-19 vaccination may induce thrombotic complications, the objective …

Antiphospholipid antibodies (aPLs), present in 1–5% of healthy individuals, are associated
with the risk of antiphospholipid syndrome (APS), which is the most common form of …

The presence of antiphospholipid antibodies was shown to be associated with thrombosis in
coronavirus disease 2019 (COVID-19) patients. Recently, according to reports from several …

Antiphospholipid syndrome and the coagulopathy of COVID-19 share many
pathophysiologic features, including endotheliopathy, hypercoagulability, and activation of …

Background: COVID-19 clinical features include a hypercoagulable state that resembles the
antiphospholipid syndrome (APS), a disease characterized by thrombosis and presence of …

Abstract Background Coronavirus disease 19 (COVID‐19)–associated coagulopathy is a
hallmark of disease severity and poor prognosis. The key manifestations of this …